AAI/CML claims clinical material production time reductions of 65%

By .

- Last updated on GMT

Image: iStock/Supertruper
Image: iStock/Supertruper

Related tags: Pharmacology

AAIPharma and Cambridge Major Labs (CML) under a merged entity have driven efficiencies in end-to-end drug manufacturing, the firm says, dramatically reducing material delivery time.

AAI Pharma and CML merged in 2013​, to form a full-service contract manufacturing organisation (CMO) and two-and-a-half years on the firm has said the integration between the two units has led to “dramatic advancements in efficiency.”

According to the CMO, it has managed to manufacture and release late-stage clinical trial materials from an active pharmaceutical ingredient (API) made under GMP, through to the sterile drug product within 79 days.

This is around 65% of the 230 days AAI/CML said is the industry standard for non-integrated approaches, and marks the first time the company has produced both GMP API and GMP Drug Product in continuous end-to-end fashion.

“We have streamlined and integrated to create world class solution for small to mid-sized pharma & biotech companies for clinical trial material by providing a broad range of services across all seven of our sites and businesses,”​ CEO Stephan Kutzer said in a statement.

“Our technical and regulatory expertise differentiates AAI/CML as we proactively guide and advise our clients through all the clinical phases. The integrated manufacturing services further complement our ProForm SelectTM service offering for a fuller end-to-end solution.”

The announcement comes weeks after the CMO announced it was investing $11m (€10m)​ into a new facility at its Cortex innovation centre in St Louis, Missouri.

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more